8-K Announcements
6Material company update
Mar 17, 2026·SEC
Material company update
Feb 23, 2026·SEC
Material company update
Feb 3, 2026·SEC
BioNexus Gene Lab Corp.(BGLC)Earnings, Financials & Key Ratios
BGLC•NASDAQ
$2.08
$4M mkt cap·Price updated May 7, 2026
AboutBioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.Show more
- Revenue$10M-2.7%
- EBITDA-$1M+42.8%
- Net Income-$2M+39.2%
- EPS (Diluted)-0.90+41.2%
- Gross Margin13.56%-0.4%
- EBITDA Margin-14.94%+41.3%
- Operating Margin-16.55%+37.7%
- Net Margin-16.81%+37.5%
- ROE-17.78%+44.8%
- ROIC-29.39%+35.9%
- Debt/Equity0.03+66.7%
- Interest Coverage-74.42+60.0%
BGLC Key Insights
BioNexus Gene Lab Corp. (BGLC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 137.1%
- ✓Trading at only 0.4x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 6 (bottom 6%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BGLC Price & Volume
BioNexus Gene Lab Corp. (BGLC) stock price & volume — 10-year historical chart
Loading chart...
BGLC Growth Metrics
BioNexus Gene Lab Corp. (BGLC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years137.09%
3 Years-10.72%
TTM2.22%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-143.67%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-140.21%
Return on Capital
10 Years-34.97%
5 Years-1.12%
3 Years-17.61%
Last Year-17.24%
BGLC Peer Comparison
BioNexus Gene Lab Corp. (BGLC) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 QDEL | 733.24M | 10.77 | -0.65 | -1.89% | -45.57% | -56.31% | 1.46 | |
 CLOV | 1.44B | 2.82 | -16.59 | 40.34% | -2.58% | -17.08% | ||
 RNAZ | 6.67M | 8.00 | -0.17 | -1.9% | ||||
 AEYE | 100.43M | 8.09 | -32.36 | 14.52% | -7.63% | -47.8% | 0.15 | |
 IDXX | 45.45B | 572.20 | 43.75 | 10.42% | 24.63% | 70.87% | 0.67 | |
 NTRA | 31.16B | 219.82 | -144.62 | 35.9% | -9.03% | -15.28% | 0.13 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 PACB | 498.3M | 1.65 | -0.91 | 3.89% | -341.47% | -11.23% | 141.98 |
Compare BGLC vs Peers
BioNexus Gene Lab Corp. (BGLC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BGLC Income Statement
BioNexus Gene Lab Corp. (BGLC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 107.68K | 212.33K | 126.95K | 11.39M | 13.36M | 10.93M | 9.77M | 9.51M | 9.47M |
| Revenue Growth % | - | - | 97.18% | -40.21% | 8872.03% | 17.31% | -18.21% | -10.6% | -2.66% | 2.22% |
| Cost of Goods Sold | 0 | 28.87K | 183.56K | 71.07K | 9.67M | 11.17M | 9.67M | 8.44M | 8.22M | 8.07M |
| COGS % of Revenue | - | 26.81% | 86.45% | 55.98% | 84.9% | 83.58% | 88.48% | 86.39% | 86.44% | - |
| Gross Profit | 0▲ 0% | 78.81K▲ 0% | 28.77K▼ 63.5% | 55.89K▲ 94.3% | 1.72M▲ 2977.3% | 2.19M▲ 27.6% | 1.26M▼ 42.6% | 1.33M▲ 5.6% | 1.29M▼ 3.0% | 1.4M▲ 0% |
| Gross Margin % | - | 73.19% | 13.55% | 44.02% | 15.1% | 16.42% | 11.52% | 13.61% | 13.56% | 14.77% |
| Gross Profit Growth % | - | - | -63.5% | 94.29% | 2977.27% | 27.56% | -42.61% | 5.6% | -3.01% | - |
| Operating Expenses | 835 | 206.72K | -31.14K | 331.59K | 446K | 1.14M | 1.55M | 3.92M | 2.86M | 3.75M |
| OpEx % of Revenue | - | 191.97% | -14.66% | 261.19% | 3.92% | 8.52% | 14.18% | 40.15% | 30.11% | - |
| Selling, General & Admin | 835 | 206.72K | 241.93K | 356.64K | 1.33M | 1.2M | 1.73M | 3.04M | 4M | 1.34M |
| SG&A % of Revenue | - | 191.97% | 113.94% | 280.92% | 11.7% | 9.01% | 15.83% | 31.11% | 42.11% | - |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 54.98K | 47.51K | 87.08K |
| R&D % of Revenue | - | - | - | - | - | - | - | 0.56% | 0.5% | - |
| Other Operating Expenses | 0 | 0 | -273.07K | -25.05K | -886.94K | -66.49K | -179.28K | 828.39K | -1.19M | 2.05M |
| Operating Income | -840▲ 0% | -127.91K▼ 15127.4% | 59.9K▲ 146.8% | -275.7K▼ 560.3% | 1.27M▲ 562.0% | 1.06M▼ 17.1% | -291.18K▼ 127.6% | -2.59M▼ 790.7% | -1.57M▲ 39.3% | -2.35M▲ 0% |
| Operating Margin % | - | -118.79% | 28.21% | -217.17% | 11.18% | 7.9% | -2.66% | -26.54% | -16.55% | -24.81% |
| Operating Income Growth % | - | -15127.38% | 146.83% | -560.27% | 562.02% | -17.11% | -127.58% | -790.73% | 39.32% | - |
| EBITDA | -5 | -112.88K | 100.51K | -222.37K | 1.38M | 1.16M | -185.76K | -2.49M | -1.42M | -2.18M |
| EBITDA Margin % | - | -104.83% | 47.34% | -175.16% | 12.08% | 8.71% | -1.7% | -25.43% | -14.94% | -23.04% |
| EBITDA Growth % | - | -2257480% | 189.04% | -321.24% | 718.52% | -15.37% | -115.96% | -1237.85% | 42.84% | -186.51% |
| D&A (Non-Cash Add-back) | 835 | 15.03K | 40.61K | 53.33K | 101.6K | 108.22K | 105.42K | 108.42K | 153.14K | 168.13K |
| EBIT | -835 | -119.42K | 59.9K | -275.7K | 1.27M | 1.06M | -291.18K | -2.59M | -1.57M | -2.32M |
| Net Interest Income | 0 | 0 | 0 | 0 | -11.31K | -12.97K | -12.48K | -13.93K | 126.5K | 206.16K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 147.64K | 221.75K |
| Interest Expense | 0 | 0 | 0 | 0 | 11.31K | 12.97K | 12.48K | 13.93K | 21.15K | 15.6K |
| Other Income/Expense | 5 | 0 | 0 | 0 | -11.31K | -12.97K | -12.48K | -13.93K | -21.15K | -22.08K |
| Pretax Income | -835▲ 0% | -119.41K▼ 14201.1% | 59.9K▲ 150.2% | -275.7K▼ 560.3% | 1.26M▲ 557.9% | 1.04M▼ 17.4% | -303.66K▼ 129.1% | -2.61M▼ 758.7% | -1.59M▲ 38.8% | -2.37M▲ 0% |
| Pretax Margin % | - | -110.9% | 28.21% | -217.17% | 11.08% | 7.8% | -2.78% | -26.69% | -16.77% | -25.05% |
| Income Tax | 0 | 4.34K | 33.45K | -29.24K | 168.41K | 291.28K | 52.31K | 21.53K | 3.49K | -73.71K |
| Effective Tax Rate % | 0% | -3.63% | 55.84% | 10.6% | 13.34% | 27.93% | -17.23% | -0.83% | -0.22% | 3.11% |
| Net Income | -835▲ 0% | -123.75K▼ 14720.4% | 26.45K▲ 121.4% | -246.47K▼ 1031.7% | 1.09M▲ 543.9% | 751.57K▼ 31.3% | -355.97K▼ 147.4% | -2.63M▼ 638.6% | -1.6M▲ 39.2% | -2.3M▲ 0% |
| Net Margin % | - | -114.92% | 12.46% | -194.14% | 9.61% | 5.62% | -3.26% | -26.91% | -16.81% | -24.27% |
| Net Income Growth % | - | -14720.36% | 121.38% | -1031.69% | 543.91% | -31.31% | -147.36% | -638.57% | 39.2% | -143.67% |
| Net Income (Continuing) | -835 | -123.75K | 26.45K | -246.47K | 1.09M | 751.57K | -355.97K | -2.63M | -1.6M | -2.3M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.00▲ 0% | -0.02▼ 19800.0% | 0.00▲ 124.1% | -0.03▼ 812.5% | 1.28▲ 3842.7% | 0.53▼ 58.6% | -0.25▼ 147.2% | -1.53▼ 512.0% | -0.90▲ 41.2% | -1.28▲ 0% |
| EPS Growth % | - | - | 124.12% | - | 3842.69% | -58.59% | -147.17% | -512% | 41.18% | -140.21% |
| EPS (Basic) | -0.00 | -0.02 | 0.00 | -0.03 | 1.28 | 0.53 | -0.25 | -1.53 | -0.90 | - |
| Diluted Shares Outstanding | 621.9K | 621.9K | 552.8K | 719.74K | 857.65K | 1.43M | 1.44M | 1.72M | 1.78M | 1.8M |
| Basic Shares Outstanding | 621.9K | 621.9K | 552.8K | 719.74K | 857.65K | 1.43M | 1.44M | 1.72M | 1.78M | 1.8M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BGLC Balance Sheet
BioNexus Gene Lab Corp. (BGLC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 26 | 999.72K | 1.3M | 882.57K | 7.99M | 7.08M | 6.02M | 8.05M | 7.43M | 5.63M |
| Cash & Short-Term Investments | 26 | 839.14K | 1.26M | 859.08K | 2.79M | 2.12M | 2.12M | 5.93M | 4.38M | 2.89M |
| Cash Only | 26 | 839.14K | 659.24K | 859.08K | 2.79M | 2.12M | 2.12M | 5.93M | 4.38M | 2.89M |
| Short-Term Investments | 0 | 0 | 601K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 2.86K | 4M | 3.36M | 2.9M | 857.26K | 1.58M | 1.63M |
| Days Sales Outstanding | - | - | - | 8.22 | 128.15 | 91.69 | 96.85 | 32.02 | 60.65 | 68.24 |
| Inventory | 0 | 32.09K | 15.3K | 7.58K | 1.18M | 1.52M | 977.81K | 1.14M | 1.39M | 1.01M |
| Days Inventory Outstanding | - | 405.65 | 30.42 | 38.93 | 44.39 | 49.74 | 36.91 | 49.2 | 61.65 | 54.19 |
| Other Current Assets | 0 | 125.94K | 22.81K | 13.06K | 22.64K | 79.52K | 25.24K | 122.43K | 84.17K | 98.9K |
| Total Non-Current Assets | 0 | 273.16K | 353.88K | 348.67K | 2.13M | 2.49M | 2.72M | 3.35M | 3M | 1.99M |
| Property, Plant & Equipment | 0 | 273.16K | 341.81K | 336.45K | 1.85M | 1.68M | 1.57M | 1.65M | 1.74M | 1.76M |
| Fixed Asset Turnover | - | 0.39x | 0.62x | 0.38x | 6.16x | 7.98x | 6.97x | 5.91x | 5.47x | 5.40x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 12.08K | 12.21K | 281.67K | 749.03K | 1.15M | 1.7M | 1.27M | 3.96M |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 67.61K | 0 | 0 | 0 | 0 |
| Total Assets | 26▲ 0% | 1.27M▲ 4895592.3% | 1.65M▲ 29.8% | 1.23M▼ 25.5% | 10.12M▲ 721.6% | 9.57M▼ 5.3% | 8.74M▼ 8.7% | 11.4M▲ 30.4% | 10.43M▼ 8.5% | 7.62M▲ 0% |
| Asset Turnover | - | 0.08x | 0.13x | 0.10x | 1.13x | 1.40x | 1.25x | 0.86x | 0.91x | 1.02x |
| Asset Growth % | - | 4895592.31% | 29.8% | -25.48% | 721.56% | -5.35% | -8.71% | 30.43% | -8.47% | -69.65% |
| Total Current Liabilities | 1.34K | 1.17M | 62.89K | 51.57K | 3.37M | 2.33M | 2M | 1.63M | 1.95M | 678.02K |
| Accounts Payable | 1.34K | 35.09K | 0 | 0 | 3.17M | 2.01M | 1.86M | 1.4M | 1.5M | 184.6K |
| Days Payables Outstanding | - | 443.65 | - | - | 119.67 | 65.76 | 70.25 | 60.63 | 66.74 | 47.94 |
| Short-Term Debt | 0 | 0 | 0 | 32.14K | 45.75K | 39.51K | 16.57K | 13.2K | 0 | 56.8K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 107.58K | 23.12K | 0 | 95.88K | 140.46K |
| Other Current Liabilities | -1.34K | 1.04M | 11.15K | 19.44K | 95.88K | 71.81K | 103.37K | 180.91K | 301.28K | 425.36K |
| Current Ratio | 0.02x | 0.85x | 20.64x | 17.11x | 2.37x | 3.04x | 3.00x | 4.93x | 3.81x | 3.81x |
| Quick Ratio | 0.02x | 0.82x | 20.40x | 16.97x | 2.02x | 2.39x | 2.52x | 4.24x | 3.10x | 3.10x |
| Cash Conversion Cycle | - | - | - | - | 52.87 | 75.67 | 63.51 | 20.59 | 55.55 | 74.5 |
| Total Non-Current Liabilities | 0 | 4.57K | 67.42K | 57.3K | 79.54K | 65.86K | 71.07K | 111.02K | 159.74K | 126.94K |
| Long-Term Debt | 0 | 0 | 0 | 45.09K | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 62.94K | 12.21K | 77.67K | 37.44K | 40.21K | 98.76K | 159.74K | 575.97K |
| Deferred Tax Liabilities | 0 | 4.57K | 0 | 0 | 1.87K | 28.42K | 30.87K | 12.26K | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 4.49K | 0 | 0 | 0 | 0 | 12.26K | 0 | 0 |
| Total Liabilities | 1.34K | 1.18M | 130.31K | 108.87K | 3.45M | 2.39M | 2.08M | 1.74M | 2.11M | 804.97K |
| Total Debt | 0 | 0 | 82.06K | 89.44K | 123.42K | 76.95K | 56.77K | 146.59K | 210.56K | 183.75K |
| Net Debt | -26 | -839.14K | -577.17K | -769.64K | -2.66M | -2.05M | -2.06M | -5.78M | -4.17M | -2.71M |
| Debt / Equity | - | - | 0.05x | 0.08x | 0.02x | 0.01x | 0.01x | 0.02x | 0.03x | 0.03x |
| Debt / EBITDA | - | - | 0.82x | - | 0.09x | 0.07x | - | - | - | -0.08x |
| Net Debt / EBITDA | - | - | -5.74x | - | -1.94x | -1.76x | - | - | - | 1.24x |
| Interest Coverage | - | - | - | - | 112.60x | 81.39x | -23.33x | -186.20x | -74.42x | -148.94x |
| Total Equity | -1.31K▲ 0% | 94.63K▲ 7317.8% | 1.52M▲ 1508.4% | 1.12M▼ 26.3% | 6.66M▲ 493.6% | 7.18M▲ 7.8% | 6.67M▼ 7.2% | 9.66M▲ 44.9% | 8.32M▼ 13.8% | 6.82M▲ 0% |
| Equity Growth % | - | 7317.85% | 1508.36% | -26.25% | 493.58% | 7.77% | -7.17% | 44.9% | -13.82% | -79.25% |
| Book Value per Share | -0.00 | 0.15 | 2.75 | 1.56 | 7.77 | 5.03 | 4.63 | 5.61 | 4.67 | 3.79 |
| Total Shareholders' Equity | -1.31K | 94.63K | 1.52M | 1.12M | 6.66M | 7.18M | 6.67M | 9.66M | 8.32M | 6.82M |
| Common Stock | 0 | 5.21M | 6.65M | 6.48M | 10.78M | 10.78M | 10.93M | 17.19M | 17.33M | 17.33M |
| Retained Earnings | -1.44K | -113.3K | -86.84K | -333.31K | 760.79K | 1.51M | 1.16M | -1.84M | -3.44M | -5.39M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 126 | 14.05K | -5.04M | -17.1K | 133.68K | -100.26K | -409.06K | -677.29K | -555K | -112.55K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BGLC Cash Flow Statement
BioNexus Gene Lab Corp. (BGLC) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -835 | 357.22K | -274.08K | -217.27K | 552.68K | 9.16K | 551.82K | -1.76M | -2.23M | -2.23M |
| Operating CF Margin % | - | 331.74% | -129.08% | -171.14% | 4.85% | 0.07% | 5.05% | -18.02% | -23.49% | - |
| Operating CF Growth % | - | 42880.36% | -176.73% | 20.73% | 354.37% | -98.34% | 5923.6% | -419.09% | -26.89% | -2035.21% |
| Net Income | -835 | -123.75K | 26.45K | -246.47K | 1.09M | 751.57K | -355.97K | -2.63M | -1.6M | -2.3M |
| Depreciation & Amortization | 0 | 15.03K | 40.61K | 53.33K | 101.6K | 108.22K | 105.42K | 108.42K | 153.14K | 168.13K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | -382.62K | 0 | 0 | -745.38K | 11.62K | -31.02K | 641.84K | -904.46K | -20.42K |
| Working Capital Changes | 0 | 439.31K | -341.14K | -24.14K | 102.36K | -862.25K | 833.38K | 117.98K | 115.4K | -700.48K |
| Change in Receivables | 0 | -6.49K | 105.67K | 9.76K | 411.07K | 579.22K | 538.65K | 606.16K | 147.76K | -242.59K |
| Change in Inventory | 0 | -32.09K | 16.79K | 7.72K | 147.04K | -345.75K | 544.11K | -160.39K | -250.85K | 381.63K |
| Change in Payables | 0 | 477.88K | 0 | 0 | -524.24K | 0 | 0 | -381.29K | 0 | -652.72K |
| Cash from Investing | 0 | -5.31M | -51.7K | -12.82K | 1.32M | -490.57K | -450.5K | -1.86M | 418.2K | 1.43M |
| Capital Expenditures | 0 | -314.82K | -39.62K | -12.82K | -421.62K | -3.16K | -54.17K | -149.4K | -226.99K | -40.02K |
| CapEx % of Revenue | - | 292.37% | 18.66% | 10.1% | 3.7% | 0.02% | 0.5% | 1.53% | 2.39% | - |
| Acquisitions | 0 | -5M | 0 | 0 | 346.01K | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 1.47M | 22.04K | 115.38K | -1.41M | 147.98K | -76.08K |
| Cash from Financing | 638 | 5.78M | 742.94K | -180.81K | -4.95K | -28.22K | 108.17K | 6.27M | 144.97K | 171.91K |
| Debt Issued (Net) | 0 | 0 | 0 | -16.78K | -4.95K | -26.3K | -34.04K | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 150K | 1000K | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 638 | 5.78M | 742.94K | -164.03K | 0 | -1.92K | -7.79K | 524.94K | 144.97K | 171.91K |
| Net Change in Cash | -108▲ 0% | 839.12K▲ 777062.0% | 421.09K▼ 49.8% | -401.16K▼ 195.3% | 1.93M▲ 580.8% | -663.77K▼ 134.4% | -5.05K▲ 99.2% | 3.81M▲ 75480.3% | -1.63M▼ 142.8% | -1.27M▲ 0% |
| Free Cash Flow | -835▲ 0% | 42.4K▲ 5177.2% | -313.7K▼ 839.9% | -230.09K▲ 26.7% | 131.06K▲ 157.0% | 6K▼ 95.4% | 497.65K▲ 8195.6% | -1.91M▼ 483.8% | -2.46M▼ 28.8% | -2.89M▲ 0% |
| FCF Margin % | - | 39.37% | -147.74% | -181.24% | 1.15% | 0.04% | 4.55% | -19.55% | -25.88% | -30.53% |
| FCF Growth % | - | 5177.25% | -839.95% | 26.65% | 156.96% | -95.42% | 8195.57% | -483.84% | -28.85% | -10.36% |
| FCF per Share | -0.00 | 0.07 | -0.57 | -0.32 | 0.15 | 0.00 | 0.35 | -1.11 | -1.38 | -1.38 |
| FCF Conversion (FCF/Net Income) | 1.00x | -2.89x | -10.36x | 0.88x | 0.51x | 0.01x | -1.55x | 0.67x | 1.40x | 1.26x |
| Interest Paid | 0 | 0 | 4.32K | 5.05K | 11.31K | 12.97K | 12.48K | 0 | 9.35K | 3.17K |
| Taxes Paid | 0 | 0 | 0 | 10.71K | 143.5K | 226.77K | 170.45K | 0 | 40.38K | 12.51K |
BGLC Key Ratios
BioNexus Gene Lab Corp. (BGLC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -265.23% | 3.27% | -18.64% | 28.11% | 10.86% | -5.14% | -32.21% | -17.78% | -33.7% |
| Return on Invested Capital (ROIC) | - | 44.87% | -31.87% | 43.92% | 17.35% | -4.49% | -45.89% | -29.39% | -29.39% |
| Gross Margin | 73.19% | 13.55% | 44.02% | 15.1% | 16.42% | 11.52% | 13.61% | 13.56% | 14.77% |
| Net Margin | -114.92% | 12.46% | -194.14% | 9.61% | 5.62% | -3.26% | -26.91% | -16.81% | -24.27% |
| Debt / Equity | - | 0.05x | 0.08x | 0.02x | 0.01x | 0.01x | 0.02x | 0.03x | 0.03x |
| Interest Coverage | - | - | - | 112.60x | 81.39x | -23.33x | -186.20x | -74.42x | -148.94x |
| FCF Conversion | -2.89x | -10.36x | 0.88x | 0.51x | 0.01x | -1.55x | 0.67x | 1.40x | 1.26x |
| Revenue Growth | - | 97.18% | -40.21% | 8872.03% | 17.31% | -18.21% | -10.6% | -2.66% | 2.22% |
BGLC SEC Filings & Documents
BioNexus Gene Lab Corp. (BGLC) SEC filings — annual & quarterly reports (10-K, 10-Q)
BGLC Frequently Asked Questions
BioNexus Gene Lab Corp. (BGLC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BioNexus Gene Lab Corp. (BGLC) reported $9.5M in revenue for fiscal year 2024.
BioNexus Gene Lab Corp. (BGLC) saw revenue decline by 2.7% over the past year.
BioNexus Gene Lab Corp. (BGLC) reported a net loss of $2.3M for fiscal year 2024.
Dividend & Returns
BioNexus Gene Lab Corp. (BGLC) has a return on equity (ROE) of -17.8%. Negative ROE indicates the company is unprofitable.
BioNexus Gene Lab Corp. (BGLC) had negative free cash flow of $2.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More BGLC
BioNexus Gene Lab Corp. (BGLC) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates